Herpes zoster in rheumatoid arthritis and in relation to biologic/targeted synthetic disease modifying anti-rheumatic drugs: a Swedish national study.
OBJECTIVE: To assess and compare the incidences of herpes zoster (HZ) in rheumatoid arthritis patients (RA) receiving biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), in b/tsDMARD-naïve RA, and general population. METHODS: We identified all patients with RA in Sweden 2014-2024, and b/tsDMARD starts among them, through register linkages. For each b/ts-DMARD treatment start, five age/sex-matched population controls were selected. A history of HZ was defined as a listing with an ICD-10 code for HZ and/or dispensation of an antiviral drug up to one year before treatment start. Incident HZ was defined as the first HZ ICD-10 code during follow-up accompanied by prescription of an antiviral within 90 days. RESULTS: 77694 unique RA patients contributed to the following: 69962 subjects in the b/tsDMARD-naïve cohort, and 20033 TNFi-, 9410 non-TNFi-, and 4023 JAKi-treatment episodes. Based on 95 incident HZ cases (incidence rate (IR) 2.0, 95% confidence interval 1.6-2.4 per1000 person-years) with TNFi, 55 cases (IR 2.4, 95% CI 1.8-3.1) with non-TNFi, 41 cases (IR 5.1, 95% CI 3.7-6.9) with JAKi, 561 cases (IR 1.5, 95% CI 1.4-1.6) in b/tsDMARD-naive RA and 494 cases (IR 0.6, 95% CI 0.6-0.7) in the general population, the multivariable-adjusted hazard ratio (using TNFi as reference) with JAKi was HR = 1.9; 95% CI 1.2-3.0 and HR = 0.9; 95% CI 0.6-1.3 for non-TNFi. CONCLUSION: The incidence of a first ever HZ is higher in b/tsDMARD-naïve patients compared to general population, is further and similarly increased in patients receiving TNFi or non-TNFi, and yet higher in those starting JAKi.
Authors
- Johan Karlsson Wallman (ORCID: https://orcid.org/0000-0002-4915-2924)
- Daniela Di Giuseppe (ORCID: https://orcid.org/0000-0003-3817-8288)
- Martin Björklund (ORCID: https://orcid.org/0000-0001-7543-4397)
- Johan Askling (ORCID: https://orcid.org/0000-0003-0433-0616)
- Alf Kastbom (ORCID: https://orcid.org/0000-0001-7187-1477)
- Jón Thorkell Einarsson (ORCID: https://orcid.org/0000-0003-3206-7050)
- Meliha Crnkic Kapetanovic (ORCID: https://orcid.org/0000-0002-7853-514X)
- Carl Turesson (ORCID: https://orcid.org/0000-0002-3805-2290)
- Gerd-Marie Alenius
- Anna Deminger (ORCID: https://orcid.org/0000-0001-6423-1623)
- Helena Forsblad‐d’Elia (ORCID: https://orcid.org/0000-0001-7871-5303)
- Lars Klareskog (ORCID: https://orcid.org/0000-0001-9601-6186)
- Lotta Ljung (ORCID: https://orcid.org/0000-0001-8999-0925)
- Bénédicte Delcoigne (ORCID: https://orcid.org/0000-0002-2716-5679)
- Valgerður Sigurðardóttir (ORCID: https://orcid.org/0000-0002-9907-4901)
- Aikaterini Chatzidionysiou
Institutions
- Linköping University (SE)
- Uppsala University (SE)
- Lund University (SE)
- Karolinska Institutet (SE)
- Falun Hospital (SE)
- Center for Clinical Research Dalarna (SE)
- Stockholm Health Care Services (SE)
- Region Östergötland (SE)
- University of Gothenburg (SE)
- Umeå University (SE)
Publication Details
- Journal
- PubMed
- Published
- 2026-11-13
- DOI
- https://doi.org/10.1093/rheumatology/keag642
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00